Natural Killer Group 2 Member D ligand (NKG2DL) (NKG2DL)

Natural Killer Group 2 Member D ligands (NKG2DLs) are a diverse group of cell surface glycoproteins, including MICA, MICB, and the ULBP family (ULBP1-6), that serve as critical signals for immune recognition. These ligands are typically absent or expressed at low levels on healthy cells but are rapidly upregulated in response to cellular stressors such as DNA damage, oxidative stress, viral infection, or oncogenic transformation (PMID: 31156643). Once expressed, they are recognized by the activating receptor NKG2D (KLRK1) found on Natural Killer (NK) cells and certain T cell subsets, triggering a potent cytotoxic response to eliminate the compromised cell (PMID: 29507053). In many cancers, tumors employ immune evasion strategies by proteolytically shedding these ligands from their surface using metalloproteinases like ADAM10 and ADAM17, which reduces the density of activating signals and generates soluble decoys that desensitize immune effectors (PMID: 28355182). Therapeutic strategies targeting the NKG2D-NKG2DL axis are currently a major focus in immuno-oncology. These include monoclonal antibodies designed to stabilize surface expression by preventing shedding, bispecific antibodies that recruit NK cells to tumor sites, and CAR-T or CAR-NK cells engineered with NKG2D-based recognition domains (PMID: 29590064). Clinical candidates such as CYAD-01 and CYAD-02 have explored the efficacy of NKG2D-based CAR-T cells across various malignancies. Despite their promise, therapeutic challenges include potential on-target, off-tumor toxicity if ligands are expressed on healthy tissues under inflammatory stress, as well as the systemic immunosuppression caused by high levels of soluble ligand decoys in the tumor microenvironment.

Other names

MICAMICBULBPUL16-binding proteinRAET1Stress-induced ligandsNKG2D-L

NKG2D receptor activation, Inhibition of ligand shedding, CAR-mediated cytotoxicity, Antibody-dependent cellular cytotoxicity (ADCC)